Vascular Gene Therapy in the 21st Century

Alexander W Clowes

doi:10.1055/s-0038-1657597

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(01): 605-610
DOI: 10.1055/s-0038-1657597

Plenary Lecture

Schattauer GmbH Stuttgart

Vascular Gene Therapy in the 21st Century

Alexander W Clowes

Department of Surgery, University of Washington School of Medicine, Seattle, WA, USA

› Author Affiliations

Abstract

PDF Download

PDF (1351 kb)

References

References
1 Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 01: 964-966
2 Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932
3 Nabel EG, Nabel GJ. Gene transfer. In: Fuster V, Ross R, Topol EJ. eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven. 1996: 739-756
4 Finkel T, Epstein SE. Gene therapy for vascular disease. FASEB J 1995; 09: 843-851
5 Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989; 80: 1347-1353
6 Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989; 244: 1344-1346
7 Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244: 1342-1344
8 Miller AD, Trauber DR, Buttimore C. Factors involved in production of helper virus-free retrovirus vectors. Somatic Cell Mol Genet 1986; 12: 175-183
9 Gordon EM, Anderson WF. Gene therapy using retroviral vectors. Curr Opin Biotechnol 1994; 05: 611-616
10 Rivière I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737
11 Weiss AA, Tailor CS. Retrovirus receptors. Cell 1995; 82: 531-533
12 Russ AP, Friedel C, Grez M, Von Melchner H. Self-deleting retrovirus vectors for gene therapy. J Virol 1996; 70: 4927-4932
13 Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WRA, Clowes AW. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994; 93: 644-651
14 Casscells W, Willerson JT. Amphotropic but not atherotropic: Another caveat for adenoviral gene therapy. J Clin Invest 1995; 95: 2425-2426
15 Berns KI, Giraud C. Adenovirus and adeno-associated virus as vectors for gene therapy. Ann.NY Acad.Sci 1995; 772: 95-104
16 Marconi P, Krisky D, Oligino T. et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320
17 Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 05: 793-801
18 Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: Focus on cytomegalovirus. Lancet 1996; 348: S13-S17
19 Hendrix MGR, Salimans MMM, Van Boven CPA, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23-28
20 Ledley FD. Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum Gene Ther 1995; 06: 1129-1144
21 Feigner PL, Tsai YJ, Sukhu L. et al. Improved cationic lipid formulations for in vivo gene therapy. Ann.NY Acad.Sci 1995; 772: 126-139
22 Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral Hposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11421-11425
23 Grossman M, Raper SE, Kozarsky K. et al. Successful ex vivo gene therapy directed to liver in a patient with familial hyperc-holesterolaemia. Nature Genet 1994; 06: 335-341
24 Raper SE, Grossman M, Rader DJ. et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996; 223: 116-126
25 Kay MA, Landen CN, Rothenberg SR. et al. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357
26 Messina LM, Podrazik RM, Whitehill TA. et al. Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat. Proc Natl Acad Sci USA 1992; 89: 12018-12022
27 Osborne WRA, Ramesh N, Lau S, Clowes MM, Dale DC, Clowes AW. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 1995; 92: 8055-8058
28 Setoguchi Y, Danel C, Crystal RG. Stimulation of erythropoi-esis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 1994; 84: 2946-2953
29 Hamamori Y, Samal B, Tian J, Kedes L. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 1995; 95: 1808-1813
30 Tripathy SK, Svensson EC, Black HB. et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93: 10876-10880
31 Örtenwall P, Wadenvik H, Risberg B. Reduced platelet deposition on seeded versus unseeded segments of expanded polytetrafluoroethylene grafts: Clinical observations after a 6-month follow-up. J Vase Surg 1989; 10: 374-380
32 Magometschnigg H, Kadletz M, Vodrazka M. et al. Prospective clinical study with in vitro endothelial cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction. J Vase Surg 1992; 15: 527-535
33 Zilla P, Deutsch M, Meinhart J. et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: An actuarial follow-up over three years. J Vase Surg 1994; 19: 540-548
34 Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301-309
35 Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med 1996; 02: 293-298
36 Dzau VJ, Morishita R, Gibbons GH. Gene therapy for cardiovascular disease. Trends Biotechnol 1993; 11: 205-210
37 Von der Leyen HE, Gibbons GH, Morishita R. et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-1141
38 Morishita R, Gibbons GH, Horiuchi M. et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859
39 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
40 Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: Fact, fancy, and future. Circulation 1994; 90: 2070-2084
41 Fischell TA, Kharma BK, Fischell DR. et al. Low-dose, b-par-ticle emission from ‘stent’ wire results in complete, localized inhibition of smooth muscle cell proliferation. Circulation 1994; 90: 2956-2963
42 Waksman R, Robinson KA, Crocker IR. et al. Intracoronary low-dose b-irradiation inhibits neointima formation after coronary artery balloon injury in the swine restenosis model. Circulation 1995; 92: 3025-3031
43 Clowes AW. Intimal hyperplasia and graft failure. Cardiovasc Pathol 1993; 02: 179S-186S
44 Schwartz SM, DeBlois D, O’Brien ERM. The intima-Soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445-465
45 Geary RL, Williams JK, Golden D, Brown DG, Benjamin ME, Adams MR. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis – A nonhuman primate model of restenosis. Arterioscler Thromb Vase Biol 1996; 16: 34-43
46 Scott NA, Cipolla GD, Ross CE. et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996; 93: 2178-2187
47 Mattsson E, Clowes AW. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med 1995; 05: 200-204
48 Nabel EG, Yang Z, Plautz G. et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogen-esis in arteries in vivo. Nature 1993; 362: 844-846
49 Nabel EG, Yang Z, Liptay S. et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993; 91: 1822-1829
50 Nabel EG, Shum L, Pompili VJ. et al. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocel-lular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-10763
51 Forough R, Koyama N, Hasenstab D. et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circulation Research 1996; 79: 812-820
52 Morishita R, Gibbons GH, Ellison KE. et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478
53 Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B_t and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994; 149: 13-19
54 Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisensec-myboligonucleotidesinhibitintimalarterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70
55 Epstein SE, Speir E, Finkel T. Do antisense approaches to the problem of restenosis make sense. Circulation 1993; 88: 1351-1353
56 Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by C-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-828
57 Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculoproliferative disease. Circ Res 1995; 76: 176-182
58 Villa AE, Guzman LA, Poptic EJ. et al. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995; 76: 505-513
59 Burgess TL, Fisher EF, Ross SL. et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995; 92: 4051-4055
60 Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis – Some critical considerations. Circulation 1995; 92: 1981-1993
61 Chang MW, Barr E, Seltzer J. et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522
62 Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-2268
63 Ohno T, Gordon D, San H. et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-484
64 Simari RD, San H, Rekhter M. et al. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 1996; 98: 225-235
65 Knechtle SJ, Zhai Y, Fechner J. Gene therapy in transplantation. Transplant Immunology 1997; 04: 257-264
66 Dunn PF, Newman KD, Jones M. et al. Seeding of vascular grafts with genetically modified endothelial cells – Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation 1996; 93: 1439-1446
67 Clowes AW. Improving the interface between biomaterials and the blood – The gene therapy approach. Circulation 1996; 93: 1319-1320
68 Takeshita S, Rossow ST, Kearney M. et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147: 1649-1660
69 Isner JM, Pieczek A, Schainfeld R. et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF₁₆₅ in patient with ischaemic limb. Lancet 1996; 348: 370-374
70 Allaire E, Forough R, Wang T, Clowes MM, Clowes AW. Tissue metalloproteinase inhibitor-1 (TIMP-1) overexpression prevents arterial rupture and dilation in a xenograft model. FASEB J 1997; 10: 782 [Abstract].